Karine Hovanes

US Patent:

20020169300, Nov 14, 2002

Filed:

Jan 29, 2002

Appl. No.:

10/060844

Inventors:

Marian Waterman - Irvine CA, US
Randall Holcombe - Cotode Caza CA, US
J. Marsh - Newport Beach CA, US
Karine Hovanes - Westminster CA, US
Tony Hung Li - Los Angeles CA, US

International Classification:

C07H021/02
C07H021/04
C07K001/00
C07K014/00
C07K017/00

US Classification:

536/023100, 530/350000

Abstract:

The present invention relates to the discovery that LEF1 is a new type of target gene in that it is ectopically activated in colon cancer. The pattern of this ectopic expression is unusual because it derives from selective activation of a promoter for a full-length LEF1 isoform that binds -catenin, but not a second, intronic promoter that drives expression of a dominant negative isoform. -catenin/TCF complexes can activate the promoter for full-length LEF1 suggesting that in cancer, high levels of these complexes misregulate transcription to favor a positive feedback loop for Wnt signaling by inducing selective expression of full length, -catenin sensitive forms of LEF/TCFs. The invention provides diagnostic and therapeutic methodologies based on the discoveries described herein.

US Patent:

20020187502, Dec 12, 2002

Filed:

Apr 25, 2002

Appl. No.:

10/134092

Inventors:

Marian Waterman - Irvine CA, US
Randall Holcombe - Coto de Caza CA, US
J. Marsh - Newport Beach CA, US
Karine Hovanes - Westminster CA, US
Tony Hung Li - Los Angeles CA, US

International Classification:

C12Q001/68
G01N033/574

US Classification:

435/006000, 435/007230

Abstract:

The present invention is based, in part, on the discovery that colon carcinoma, carcinogenesis, or the predisposition thereto is associated with the level of Wnt2, Wnt5, BMP6, and Fz receptors and the full-length and dominant negative form of LEF1.